Τίτλος:
Estimating seroprevalence of vaccine-preventable infections: is it worth
standardizing the serological outcomes to adjust for different assays
and laboratories?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The aim of the European Sero-Epidemiology Network 2 (ESEN2) project was
to estimate age-specific seroprevalence for a number of
vaccine-preventable diseases in Europe. To achieve this serosurveys were
collected by 22 national laboratories. To adjust for a variety of
laboratory methods and assays, all quantitative results were transformed
to a reference laboratory’s units and were then classified as positive
or negative to obtain age-specific seroprevalence. The aim of this study
was to assess the value of standardization by comparing the crude and
standardized seroprevalence estimates. Seroprevalence was estimated for
measles, mumps, rubella, diphtheria, varicella zoster and hepatitis A
virus (HAV) and compared before and after serological results had been
standardized. The results showed that if no such adjustment had taken
place, seroprevalence would have differed by an average of 3.2% (95%
bootstrap interval 2.9-3.6) although this percentage varied
substantially by antigen. These differences were as high as 16% for
some serosurveys (HAV) which means that standardization could have a
considerable impact on seroprevalence estimates and should be considered
when comparing serosurveys performed in different laboratories using
different assay methods.
Συγγραφείς:
Kafatos, G.
Andrews, N.
Mcconway, K. J.
Anastassopoulou, C.
and Barbara, C.
De Ory, F.
Johansen, K.
Mossong, J. and
Prosenc, K.
Vranckx, R.
Nardone, A.
Pebody, R. and
Farrington, P.
Περιοδικό:
Epidemiology and Infection
Εκδότης:
Cambridge University Press
Λέξεις-κλειδιά:
ESEN2; seroprevalence; serosurvey; standardization; vaccination
DOI:
10.1017/S095026881400301X
